SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Beukelman T, Xie F, Curtis JR.Usage of TNFα inhibitors for the treatment of juvenile idiopathic arthritis: data from a national U. S. administrative claims database [abstract].Arthritis Rheum2010;62 Suppl:S1001.
  • 2
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.JAMA2006;295:227585.
  • 3
    Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al.Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists.Arthritis Rheum2007;56:112533.
  • 4
    Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al.Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.Arthritis Rheum2012;64:277380.
  • 5
    Blum MA, Koo D, Doshi JA.Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review.Clin Ther2011;33:90113.
  • 6
    Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM.Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.Arthritis Rheum2008;59:107481.
  • 7
    Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al, for the CORRONA Investigators.High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.Ann Rheum Dis2011;70:78591.
  • 8
    Dao KH, Herbert M, Habal N, Cush JJ.Nonserious infections: should there be cause for serious concerns?Rheum Dis Clin North Am2012;38:70725.
  • 9
    Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Ann Rheum Dis2010;69:5228.
  • 10
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al.Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents.JAMA2009;301:73744.
  • 11
    Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al.Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis2013;72:22934.
  • 12
    Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al.Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.JAMA2013;309:88795.